GPCR · Program file
aleniglipron
Structure Therapeutics Inc. (GPCR)
When did Structure Therapeutics Inc. say aleniglipron results would come?
On , Structure Therapeutics Inc. wrote in its SEC Form 8-K: “Additional clinical data expected in the fourth quarter of 2026 could further define aleniglipron’s differentiated clinical profile in terms of the quality of weight loss, treatment of patients with T2DM and the transition from approved injectable incretin medicines. Expected data readouts include: · Phase 2 Body Composition clinical trial (NCT07169942): Results from a 44-week study evaluating aleniglipron’s effects on body fat and overall body composition. · Phase 2 T2DM clinical trial (NCT07400588): Results in adults living with T2DM and obesity or overweight. · Phase 1 SWITCH clinical trial: Results evaluating the transition from approved injectable GLP-1 medicine to once-daily oral aleniglipron.” (Source)
Days left in the window the company stated: 73 · company’s wording: “fourth quarter of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- aleniglipron
- Other names in filings
- GSBR-1290 · Phase 2 Body Composition clinical trial
- Indication in the filing
- Not stated in the filing
- Trials named in the same filing
- NCT07169942
- Latest timing wording
- “Additional clinical data expected in the fourth quarter of 2026 could further define aleniglipron’s differentiated clinical profile in terms of the quality of weight loss, treatment of patients with T2DM and the transition from approved injectable incretin medicines. Expected data readouts include: · Phase 2 Body Composition clinical trial (NCT07169942): Results from a 44-week study evaluating aleniglipron’s effects on body fat and overall body composition. · Phase 2 T2DM clinical trial (NCT07400588): Results in adults living with T2DM and obesity or overweight. · Phase 1 SWITCH clinical trial: Results evaluating the transition from approved injectable GLP-1 medicine to once-daily oral aleniglipron.”
- Source
- 8-K · filed · SEC accepted · accession 0001104659-26-105688 · SEC original
- Last checked
Program GPCR-aleniglipron.